{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:01:26Z","timestamp":1793228486661,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006090","name":"Center for Global Health","doi-asserted-by":"publisher","award":["CGH 001181"],"award-info":[{"award-number":["CGH 001181"]}],"id":[{"id":"10.13039\/100006090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>In 2016, Namibia had ~\u2009230,000 people living with HIV (PLHIV) and 9154 new tuberculosis (TB) cases, including 3410 (38%) co-infected cases. TB preventative therapy (TPT), consisting of intensive case finding and isoniazid preventative therapy, is critical to reducing TB disease and mortality.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Between November 2014 and February 2015, data was abstracted from charts of PLHIV enrolled in HIV treatment. Fifty-five facilities were purposively selected based on patient volume, type and location. Charts were randomly sampled. The primary outcome was to estimate baseline TPT in PLHIV, using nationally weighted proportions. Qualitative surveys were conducted and summarized to evaluate TPT practices and quantify challenges encountered by health care workers (HCW).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Among 861 PLHIV sampled, 96% were eligible for TPT services, of which 87.1% were screened for TB at least once. For PLHIV eligible for preventative therapy (646\/810; 82.6%), 45.4% (294\/646) initiated therapy and 45.7% (139\/294) of those completed therapy. The proportion of eligible PLHIV completing TB screening, initiating preventative therapy and then completing preventative therapy was 20.7%. Qualitative surveys with 271 HCW identified barriers to TPT implementation including: lack of training (61.3% reported receiving training on TPT); misunderstandings about timing of TPT initiation (46.7% correctly reported TPT should be started with antiretroviral therapy); and variable screening practices and responsibilities (66.1% of HCWs screened for TB at every encounter). Though barriers were evident, 72.2% HCWs surveyed described their clinical performance as very good, often placing responsibility of difficulties on patients and downplaying challenges like staff shortages and medication stock outs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In this study, only 1 in 5 eligible PLHIV completed the TPT cascade in Namibia. Lack of training, irregularities with TB screening and timing of TPT, unclear prescribing and recording responsibilities, and a clinical misperception may have contributed to suboptimal programmatic implementation. Addressing these challenges will be critical with continued TPT scale-up.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12889-020-09902-z","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T03:02:33Z","timestamp":1606791753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4237-5452","authenticated-orcid":false,"given":"Clay","family":"Roscoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"de Klerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Baughman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Agolory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gawanab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natanael","family":"Salomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negussie","family":"Taffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lowrance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Robsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Tollefson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pevzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ndapewa","family":"Hamunime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farai","family":"Mavhunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Mungunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,1]]},"reference":[{"issue":"11","key":"9902_CR1","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1086\/593017","volume":"198","author":"C Geldmacher","year":"2008","unstructured":"Geldmacher C, Schuetz A, Ngwenyama N, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis. 2008;198(11):1950.","journal-title":"J Infect Dis"},{"issue":"1","key":"9902_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00042560-200001010-00010","volume":"23","author":"CB Holmes","year":"2000","unstructured":"Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2000;23(1):75.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"9902_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1056\/NEJM199201233260404","volume":"326","author":"CL Daley","year":"1992","unstructured":"Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992;326:231.","journal-title":"N Engl J Med"},{"key":"9902_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/cid\/cis798","volume":"56","author":"T Lahey","year":"2013","unstructured":"Lahey T, Mackenzie T, Arbeit RD, et al. Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. Clin Infect Dis. 2013;56:151.","journal-title":"Clin Infect Dis"},{"key":"9902_CR5","volume-title":"Tuberculosis Fact Sheet","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Tuberculosis Fact Sheet, 2017. Accessed at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs104\/en."},{"key":"9902_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1056\/NEJM199709183371201","volume":"337","author":"CC Whalen","year":"1997","unstructured":"Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med. 1997;337:801.","journal-title":"N Engl J Med"},{"key":"9902_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2147\/TCRM.S127765","volume":"13","author":"A Abossie","year":"2017","unstructured":"Abossie A, Yohanes T. Assessment of isoniazid preventive therapy in the reduction of tuberculosis among ART patients in Arba Minch hospital, Ethiopia. Ther Clin Risk Manag. 2017;13:361\u20136.","journal-title":"Ther Clin Risk Manag"},{"key":"9902_CR8","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1016\/S2214-109X(17)30372-8","volume":"5","author":"A Badje","year":"2017","unstructured":"Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5:e1080\u20139.","journal-title":"Lancet Glob Health"},{"key":"9902_CR9","unstructured":"(http:\/\/www.unaids.org\/en\/regionscountries\/ countries\/namibia)."},{"key":"9902_CR10","unstructured":"WHO 2016 Country Profile, TB. Accessed at: https:\/\/extranet.who.int\/sree\/Reports?op=Replet&name= \/WHO_HQ_Reports\/G2\/PROD\/ EXT\/TBCountryProfile&ISO2=NA&outtype=html)."},{"key":"9902_CR11","unstructured":"WHO, 2011. Guidelines for intensified case-finding and isoniazid preventative therapy for PLHIV in resource-constrained settings. Accessed at: (http:\/\/apps.who.int\/iris\/bitstream\/10665\/44472\/ 1\/9789241500708_eng.pdf)."},{"issue":"Suppl 1: M2","key":"9902_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/1874279301307010023","volume":"7","author":"J van Gorkom","year":"2013","unstructured":"van Gorkom J, Mavhunga F, Omer AO, et al. TB Control in Namibia 2002\u20132011: Progress and Technical Assistance. Open Infect Dis J. 2013;7(Suppl 1: M2):23\u20139.","journal-title":"Open Infect Dis J"},{"issue":"12","key":"9902_CR13","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.5588\/ijtld.19.0018","volume":"23","author":"D Surie","year":"2019","unstructured":"Surie D, Interrante JD, Pathmanathan I, et al. Policies, practices and barriers to implementing tuberculosis preventive treatment-35 countries, 2017. Int J Tuberc Lung Dis. 2019;23(12):1308\u201313.","journal-title":"Int J Tuberc Lung Dis"},{"key":"9902_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1186\/s12889-016-3525-8","volume":"16","author":"G Teklay","year":"2016","unstructured":"Teklay G, Teklu T, Legesse B, et al. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health. 2016;16:840. https:\/\/doi.org\/10.1186\/s12889-016-3525-8.","journal-title":"BMC Public Health"},{"issue":"5","key":"9902_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.5588\/ijtld.16.0775","volume":"21","author":"B Maharaj","year":"2017","unstructured":"Maharaj B, Gengiah TN, Yende-Zuma N, et al. Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. Int J Tuberc Lung Dis. 2017;21(5):537\u201343.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"suppl 5","key":"9902_CR16","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1097\/01.aids.0000391023.03037.1f","volume":"24","author":"H Getahun","year":"2010","unstructured":"Getahun H, Granich R, Sculier D, et al. Implementation of isoniazid preventative therapy for PLHIV worldwide: barriers and solutuions. AIDS. 2010;24(suppl 5):S57\u201365.","journal-title":"AIDS."},{"issue":"8","key":"9902_CR17","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.5588\/ijtld.12.0240","volume":"17","author":"J Cowan","year":"2013","unstructured":"Cowan J, Cowan JG, Barnhart S, et al. A qualitative assessment of challenges to tuberculosis management and prevention in northern Ethiopia. Int J Tuberc Lung Dis. 2013;17(8):1071\u20135. https:\/\/doi.org\/10.5588\/ijtld.12.0240.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"9902_CR18","doi-asserted-by":"publisher","first-page":"e0153243","DOI":"10.1371\/journal.pone.0153243","volume":"11","author":"M Charles","year":"2016","unstructured":"Charles M, Lindegren M, Wester C, et al. Implementation of tuberculosis intensive case finding, isoniazid preventive therapy, and infection control (\u201cthree I\u2019s\u201d) and HIV-tuberculosis service integration in lower income countries. PLoS One. 2016;11(4):e0153243. https:\/\/doi.org\/10.1371\/journal.pone.0153243.","journal-title":"PLoS One"},{"issue":"suppl 5","key":"9902_CR19","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1097\/01.aids.0000391021.18284.12","volume":"24","author":"R Lester","year":"2010","unstructured":"Lester R, Hamilton R, Charalambous S, et al. Barriers to implementation of isoniazid preventative therapy in HIV clinics: a qualitative review. AIDS. 2010;24(suppl 5):S45\u20138.","journal-title":"AIDS."},{"issue":"4","key":"9902_CR20","doi-asserted-by":"publisher","first-page":"e18435","DOI":"10.1371\/journal.pone.0018435","volume":"6","author":"DA Gust","year":"2016","unstructured":"Gust DA, Mosimaneotsile B, Mathebula U, et al. Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana. PLoS One. 2016;6(4):e18435. https:\/\/doi.org\/10.1371\/journal.pone.0018435.","journal-title":"PLoS One"},{"key":"9902_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.11604\/pamj.2014.17.26.2641","volume":"17","author":"M Mindachew","year":"2016","unstructured":"Mindachew M, Deribew A, Memiah P, et al. Perceived barriers to the implementation of isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J. 2016;17:26. https:\/\/doi.org\/10.11604\/pamj.2014.17.26.2641.","journal-title":"Pan Afr Med J"},{"issue":"7","key":"9902_CR22","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1080\/09540121.2017.1283390","volume":"29","author":"KB Jacobson","year":"2016","unstructured":"Jacobson KB, Niccolai L, Mtungwa N, et al. It\u2019s about my life: facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa. AIDS Care. 2016;29(7):936\u201342. https:\/\/doi.org\/10.1080\/09540121.2017.1283390.","journal-title":"AIDS Care"},{"issue":"10","key":"9902_CR23","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.5588\/ijtld.15.0805","volume":"20","author":"HT Ayele","year":"2016","unstructured":"Ayele HT, van Mourik MS, Bonten MJ. Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia. Int J Tuberc Lung Dis. 2016;20(10):1342\u20137. https:\/\/doi.org\/10.5588\/ijtld.15.0805.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"7","key":"9902_CR24","doi-asserted-by":"publisher","first-page":"903","DOI":"10.5588\/ijtld.12.0677","volume":"17","author":"LR Codecasa","year":"2013","unstructured":"Codecasa LR, Murgia N, Ferrarese M, et al. Isoniazid preventive treatment: predictors of adverse events and treatment completion. Int J Tuberc Lung Dis. 2013;17(7):903\u20138. https:\/\/doi.org\/10.5588\/ijtld.12.0677.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"9902_CR25","doi-asserted-by":"publisher","first-page":"e87166","DOI":"10.1371\/journal.pone.0087166","volume":"9","author":"T Makanjuola","year":"2014","unstructured":"Makanjuola T, Taddese HB, Booth A. Factors associated with adherence to treatement with isoniazid for the prevention of tuberculosis amongst people living with HIV\/AIDS: a systematic review of qualitative data. PLoS One. 2014;9(2):e87166. https:\/\/doi.org\/10.1371\/journal.pone.0087166.","journal-title":"PLoS One"},{"key":"9902_CR26","volume-title":"National Guidelines for Antiretroviral Therapy, Revised Fourth Edition","author":"Republic of Namibia, Ministry of Health and Social Services","year":"2014","unstructured":"Republic of Namibia, Ministry of Health and Social Services. National Guidelines for Antiretroviral Therapy, Revised Fourth Edition. 4th ed. Windhoek, Namibia: MoHSS, DSP, NTLP, private bag 13198; 2014.","edition":"4"},{"key":"9902_CR27","volume-title":"National Guidelines for the Management of Tuberculosis","author":"Republic of Namibia, Ministry of Health and Social Services","year":"2015","unstructured":"Republic of Namibia, Ministry of Health and Social Services. National Guidelines for the Management of Tuberculosis. 5th ed. Windhoek, Namibia: MoHSS, DSP, NTLP, private bag 13198; 2015.","edition":"5"},{"key":"9902_CR28","volume-title":"National Guidelines for the Management of Tuberculosis","author":"Republic of Namibia, Ministry of Health and Social Services","year":"2010","unstructured":"Republic of Namibia, Ministry of Health and Social Services. National Guidelines for the Management of Tuberculosis. 3rd ed. Windhoek, Namibia: N, DSP, NTLP, private bag 13198; 2010.","edition":"3"},{"issue":"8","key":"9902_CR29","doi-asserted-by":"publisher","first-page":"e104557","DOI":"10.1371\/journal.pone.0104557","volume":"9","author":"KB Yirdaw","year":"2014","unstructured":"Yirdaw KB, Jerene D, Gashu Z, et al. Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia. PLoS One. 2014;9(8):e104557. https:\/\/doi.org\/10.1371\/journal.pone.0104557.","journal-title":"PLoS One"},{"issue":"1","key":"9902_CR30","doi-asserted-by":"publisher","first-page":"e1000391","DOI":"10.1371\/journal.pmed.1000391","volume":"8","author":"H Getahun","year":"2011","unstructured":"Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8(1):e1000391. https:\/\/doi.org\/10.1371\/journal.pmed.1000391.","journal-title":"PLoS Med"},{"key":"9902_CR31","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa0907488","volume":"362","author":"KP Cain","year":"2010","unstructured":"Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med. 2010;362:707\u201316.","journal-title":"N Engl J Med"},{"key":"9902_CR32","volume-title":"The birth of the clinic","author":"M Foucault","year":"1973","unstructured":"Foucault M. The birth of the clinic. New York: Pantheon Books; 1973."},{"key":"9902_CR33","doi-asserted-by":"publisher","DOI":"10.1525\/9780520340848","volume-title":"Patients and healers in the context of culture","author":"A Kleinman","year":"1980","unstructured":"Kleinman A. Patients and healers in the context of culture. Berkeley: University of California Press; 1980."},{"key":"9902_CR34","volume-title":"Biomedicine examined","year":"1988","unstructured":"Lock M, Gordon D, editors. Biomedicine examined. Boston: Kluwer; 1988."},{"issue":"6","key":"9902_CR35","doi-asserted-by":"publisher","first-page":"596","DOI":"10.5588\/ijtld.17.0758","volume":"22","author":"I Pathmanathan","year":"2019","unstructured":"Pathmanathan I, Ahmedov S, Pevzner E, et al. TB preventive therapy for people living with HIV \u2013 key considerations for scale-up in resource-limited settings. Int J Tuberc Lung Dis. 2019;22(6):596\u2013605.","journal-title":"Int J Tuberc Lung Dis"},{"key":"9902_CR36","doi-asserted-by":"publisher","first-page":"e25065","DOI":"10.1002\/jia2.25065","volume":"21","author":"AE Shapiro","year":"2018","unstructured":"Shapiro AE, van Heerden A, Schaafsma TT, et al. Completion of the tuberculosis care cascade in a community based HIV linkage-to-care study in South Africa and Uganda. J Int AIDS Soc. 2018;21:e25065.","journal-title":"J Int AIDS Soc"},{"key":"9902_CR37","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12879-020-04997-6","volume":"20","author":"M Robert","year":"2020","unstructured":"Robert M, Todd J, Ngowi BJ, et al. Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar Es Salaam region, Tanzania A cross-sectional analytical study. BMC Infect Dis. 2020;20:276.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"9902_CR38","doi-asserted-by":"publisher","first-page":"e0223076","DOI":"10.1371\/journal.pone.0223076","volume":"14","author":"S Nyathi","year":"2019","unstructured":"Nyathi S, Dlodlo RA, Satyanarayana S, et al. Isoniazid preventive therapy: uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe. PLoS One. 2019;14(10):e0223076. https:\/\/doi.org\/10.1371\/journal.pone.0223076.","journal-title":"PLoS One"},{"issue":"12","key":"9902_CR39","first-page":"329","volume":"69","author":"M Melgar","year":"2020","unstructured":"Melgar M, Nichols C, Cavanaugh S, et al. Tuberculosis preventive treatment scale-up among antiretroviral therapy patients \u2014 16 countries supported by the U.S. President\u2019s Emergency Plan for AIDS Relief, 2017\u20132019. MMWR. 2020;69(12):329\u201334.","journal-title":"MMWR."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-09902-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12889-020-09902-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-09902-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T03:04:45Z","timestamp":1606791885000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-020-09902-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9902"],"URL":"https:\/\/doi.org\/10.1186\/s12889-020-09902-z","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"25 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol was approved by the Permanent Secretary of Health, through the Biomedical Research Ethics Committee of the Research Management Unit of the Namibian Ministry of Health and Social Services, as well as reviewed in accordance with the CDC, Atlanta, GA, human research protection procedures and was determined to be routine program evaluation. Consent to participate and consent for publication were not applicable. No administrative permissions were required to access the raw data for this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1838"}}